Structure
Our Structure
Cynaptec is a biopharmaceutical company dedicated to developing innovative therapies for neurological and psychiatric disorders Cynaptec’s initial development program is focused on the use of its proprietary Conjugated Psilocin™
-
Stand-alone Delaware company
-
Separate Board of Directors
-
64% owned by Lobe Sciences, Ltd.
-
Shared services provided by Lobe under Shared Services Agreement
-
Conjugated Psilocin TM Assets and IP transferred from Lobe Sciences
Altemia® is specifically designed to treat a common deficiency created by an error in metabolism referred to as Sickle Cell Disease (SCD).
THIS PRODUCT MUST BE APPROVED BY A CERTIFIED PHYSICIAN.
-
Stand-alone operating company
-
Separate Executive Team
-
Shared services provided by Lobe under MSA
-
Medical food for dietary management of sickle cell disease in adult and pediatric patients, diabetes, chronic kidney disease
